Pay in 4 interest-free payments of $7.25 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
The statements and the products of this company are not intended to diagnose, treat, cure, or prevent any disease
Tibosovos approval was supported by data from a pivotal Phase I open-label study of 18 patients from the target population, where the drug elicited a 38.9% complete remission rate after a median of 1.9 months
Expect 12-18 months of stability
Lu and Ding, 1999)
Individual responses vary based on condition severity and other factors
US$ 26.65
US$ 27.88
US$ 23.66
US$ 20.94
US$ 23.15
US$ 25.85
US$ 23.06
US$ 20.17
US$ 20.50
US$ 29.86
US$ 21.23
US$ 27.85
US$ 27.44
US$ 28.21
